Gene Therapy Value & HTA Evolution

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, today's topics cut right to the heart of how we're reassessing value in rare disease.

MarcusExactly. We're looking at the FDA's accelerated approval for a novel SMA gene therapy — what this signals for the accelerated approval pathway. Then NICE's updated guidance on patient-reported outcomes in rare diseases — how this reshapes evidence requirements. And CMS's proposed changes to the Part D coverage gap for biologics — direct budget impact implications.

SaraThat second one hits close to home — the PRO framework evolution in rare diseases has been a long time coming, but I wonder if NICE's new emphasis will actually translate into measurable value assessments.

MarcusFair question. Let's get into it.

MarcusStarting with the FDA's accelerated approval for the new SMA gene therapy. This is a third-in-class approach with a novel vector design, granted based on surrogate endpoints. What strikes me is the continued expansion of accelerated approvals into ultra-orphan spaces where traditional endpoints are impractical.

SaraThat's one read — I'd frame it slightly differently. The part that gives me pause is the post-marketing requirement burden. We're seeing more requests for confirmatory trials in ultra-rare diseases, which creates near-impossible recruitment challenges. Payers will scrutinize these heavily.

MarcusAbsolutely. And what's interesting is the FDA's reliance on natural history controls here. They're accepting historical data as comparators, which shifts the evidentiary burden but raises questions about confounding factors. How do you see that playing out in HTA submissions?

SaraMethodologically, it's tricky. HTA bodies like NICE have historically been skeptical of single-arm trials with historical controls. But for ultra-orphan diseases, what's the alternative? This might force NICE to adapt their framework faster than expected.

MarcusThat connects to something I keep coming back to — the tension between innovation access and methodological rigor. The FDA's move could create a two-tiered system where accelerated approvals face higher value hurdles in HTA. What's your take on that?

SaraI'd push back slightly on that framing. It's not about tiers; it's about context. NICE's new PRO framework actually acknowledges that traditional endpoints don't capture the full picture in rare diseases. This could bridge the gap between regulatory and HTA assessments.

MarcusThat's a fair point. The PRO evolution might be the key here. Let's pivot to that next.

SaraNICE's updated guidance on patient-reported outcomes in rare diseases is significant. They're now explicitly requiring PROs as primary endpoints in ultra-orphan submissions, with preference for validated disease-specific measures. This moves beyond generic EQ-5D to capture patient experience.

MarcusWhat strikes me is the operational challenge. Developing validated PRO instruments takes years, especially for ultra-rare conditions. Companies will need to invest early in PRO development to align with this. Will that delay submissions?

SaraPotentially, but it's necessary. The part that gives me pause is the interpretability. How will NICE weight PRO data against clinical endpoints? There's still ambiguity in their methodology for integrating PROs into cost-effectiveness models.

MarcusThat's a crucial point. And it ties back to gene therapies — if the PRO data shows meaningful quality-of-life improvements but minimal clinical benefit, how does that translate to willingness-to-pay? We're seeing this tension in recent SMA appraisals.

SaraExactly. And from the payer side, the budget impact question is one the field hasn't fully worked out yet. High-cost ultra-orphan therapies with strong PRO data but limited mortality benefits create real opportunity cost challenges. NICE's framework might need to address this explicitly.

MarcusRight. Which leads us to the CMS Part D coverage gap changes. Proposed modifications would reduce the biologic copayment in the coverage gap from 40% to 25%, with a $2,000 annual cap. This directly impacts patient access for high-cost biologics.

SaraThe budget impact here is substantial. For gene therapies in Part D, this could reduce patient out-of-pocket costs by tens of thousands of dollars. But what's the trade-off? CMS is likely offsetting this through rebate adjustments, which may affect manufacturer pricing strategies.

MarcusThat's the unspoken consequence. If rebates increase to cover the expanded coverage, net prices might not change. But for HEOR teams, this creates new evidence requirements around long-term adherence and cost-offsets. How should companies approach this?

SaraThey need to model the impact of reduced cost-sharing on utilization patterns. Lower copays typically increase adherence, which could improve real-world effectiveness data. But proving that cost-offset in Part D is complex — CMS will demand robust evidence for any rebate adjustments.

MarcusAnd that connects to our earlier point about PROs. If patients access therapies earlier due to reduced costs, we might see different long-term PRO trajectories. This could create a virtuous cycle of evidence generation.

SaraThat's one way to see it. But I remain cautious — the CMS changes are proposed, not final. We've seen Part D modifications face industry pushback before. The real test will be whether these changes survive the rulemaking process.

MarcusFair enough. Let's wrap up with forward-looking thoughts.

SaraI'll be watching how NICE operationalizes their PRO framework in upcoming appraisals. The first test cases will reveal whether this is truly transformative or just procedural.

MarcusSame — and for me the thread running through today is the convergence of regulatory and HTA evidence requirements. The gap between accelerated approvals and traditional HTA is narrowing, which could reshape development strategies.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.